Genetic predictors of MEK dependence in non-small cell lung cancer

Christine A. Pratilas, Aphrothiti J. Hanrahan, Ensar Halilovic, Yogindra Persaud, Junichi Soh, Dhananjay Chitale, Hisayuki Shigematsu, Hiromasa Yamamoto, Ayana Sawai, Manickam Janakiraman, Barry S. Taylor, William Pao, Shinichi Toyooka, Marc Ladanyi, Adi Gazdar, Neal Rosen, David B. Solit

Research output: Contribution to journalArticle

182 Citations (Scopus)

Abstract

Hyperactivated extracellular signal-regulated kinase (ERK) signaling is common in human cancer and is often the result of activating mutations in BRAF,RAS,and upstream receptor tyrosine kinases. To characterize the mitogen-activated protein kinase/ERK kinase (MEK)/ERK dependence of lung cancers harboring BRAF kinase domain mutations,we screened a large panel of human lung cancer cell lines (n = 87) and tumors (n = 916) for BRAF mutations. We found that non-small cell lung cancers (NSCLC) cells with both V600E and non-V600E BRAF mutations were selectively sensitive to MEK inhibition compared with those harboring mutations in epidermal growth factor receptor (EGFR), KRAS, or ALK and ROS kinase fusions. Supporting its classification as a "driver" mutation in the cells in which it is expressed,MEK inhibition in V600EBRAF NSCLC cells led to substantial induction of apoptosis,comparab le with that seen with EGFR kinase inhibition in EGFR mutant NSCLC models. Despite high basal ERK phosphorylation, EGFR mutant cells were uniformly resistant to MEK inhibition. Conversely, BRAF mutant cell lines were resistant to EGFR inhibition. These data,together with the nonoverlapping pattern of EGFR and BRAF mutations in human lung cancer,suggest that these lesions define distinct clinical entities whose treatment should be guided by prospective real-time genotyping. To facilitate such an effort, we developed a mass spectrometry-based genotyping method for the detection of hotspot mutations in BRAF, KRAS,and EGFR. Using this assay,we confirmed that BRAF mutations can be identified in a minority of NSCLC tumors and that patients whose tumors harbor BRAF mutations have a distinct clinical profile compared with those whose tumors harbor kinase domain mutations in EGFR.

Original languageEnglish (US)
Pages (from-to)9375-9383
Number of pages9
JournalCancer Research
Volume68
Issue number22
DOIs
StatePublished - Nov 15 2008

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Mutation
Extracellular Signal-Regulated MAP Kinases
Lung Neoplasms
Neoplasms
Proto-Oncogene Proteins B-raf
Phosphotransferases
MAP Kinase Kinase Kinases
Cell Line
Receptor Protein-Tyrosine Kinases
Mitogen-Activated Protein Kinases
Mass Spectrometry
Phosphorylation
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D., ... Solit, D. B. (2008). Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Research, 68(22), 9375-9383. https://doi.org/10.1158/0008-5472.CAN-08-2223

Genetic predictors of MEK dependence in non-small cell lung cancer. / Pratilas, Christine A.; Hanrahan, Aphrothiti J.; Halilovic, Ensar; Persaud, Yogindra; Soh, Junichi; Chitale, Dhananjay; Shigematsu, Hisayuki; Yamamoto, Hiromasa; Sawai, Ayana; Janakiraman, Manickam; Taylor, Barry S.; Pao, William; Toyooka, Shinichi; Ladanyi, Marc; Gazdar, Adi; Rosen, Neal; Solit, David B.

In: Cancer Research, Vol. 68, No. 22, 15.11.2008, p. 9375-9383.

Research output: Contribution to journalArticle

Pratilas, CA, Hanrahan, AJ, Halilovic, E, Persaud, Y, Soh, J, Chitale, D, Shigematsu, H, Yamamoto, H, Sawai, A, Janakiraman, M, Taylor, BS, Pao, W, Toyooka, S, Ladanyi, M, Gazdar, A, Rosen, N & Solit, DB 2008, 'Genetic predictors of MEK dependence in non-small cell lung cancer', Cancer Research, vol. 68, no. 22, pp. 9375-9383. https://doi.org/10.1158/0008-5472.CAN-08-2223
Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Research. 2008 Nov 15;68(22):9375-9383. https://doi.org/10.1158/0008-5472.CAN-08-2223
Pratilas, Christine A. ; Hanrahan, Aphrothiti J. ; Halilovic, Ensar ; Persaud, Yogindra ; Soh, Junichi ; Chitale, Dhananjay ; Shigematsu, Hisayuki ; Yamamoto, Hiromasa ; Sawai, Ayana ; Janakiraman, Manickam ; Taylor, Barry S. ; Pao, William ; Toyooka, Shinichi ; Ladanyi, Marc ; Gazdar, Adi ; Rosen, Neal ; Solit, David B. / Genetic predictors of MEK dependence in non-small cell lung cancer. In: Cancer Research. 2008 ; Vol. 68, No. 22. pp. 9375-9383.
@article{f0aad5f1179041b2b6a0e47e52892674,
title = "Genetic predictors of MEK dependence in non-small cell lung cancer",
abstract = "Hyperactivated extracellular signal-regulated kinase (ERK) signaling is common in human cancer and is often the result of activating mutations in BRAF,RAS,and upstream receptor tyrosine kinases. To characterize the mitogen-activated protein kinase/ERK kinase (MEK)/ERK dependence of lung cancers harboring BRAF kinase domain mutations,we screened a large panel of human lung cancer cell lines (n = 87) and tumors (n = 916) for BRAF mutations. We found that non-small cell lung cancers (NSCLC) cells with both V600E and non-V600E BRAF mutations were selectively sensitive to MEK inhibition compared with those harboring mutations in epidermal growth factor receptor (EGFR), KRAS, or ALK and ROS kinase fusions. Supporting its classification as a {"}driver{"} mutation in the cells in which it is expressed,MEK inhibition in V600EBRAF NSCLC cells led to substantial induction of apoptosis,comparab le with that seen with EGFR kinase inhibition in EGFR mutant NSCLC models. Despite high basal ERK phosphorylation, EGFR mutant cells were uniformly resistant to MEK inhibition. Conversely, BRAF mutant cell lines were resistant to EGFR inhibition. These data,together with the nonoverlapping pattern of EGFR and BRAF mutations in human lung cancer,suggest that these lesions define distinct clinical entities whose treatment should be guided by prospective real-time genotyping. To facilitate such an effort, we developed a mass spectrometry-based genotyping method for the detection of hotspot mutations in BRAF, KRAS,and EGFR. Using this assay,we confirmed that BRAF mutations can be identified in a minority of NSCLC tumors and that patients whose tumors harbor BRAF mutations have a distinct clinical profile compared with those whose tumors harbor kinase domain mutations in EGFR.",
author = "Pratilas, {Christine A.} and Hanrahan, {Aphrothiti J.} and Ensar Halilovic and Yogindra Persaud and Junichi Soh and Dhananjay Chitale and Hisayuki Shigematsu and Hiromasa Yamamoto and Ayana Sawai and Manickam Janakiraman and Taylor, {Barry S.} and William Pao and Shinichi Toyooka and Marc Ladanyi and Adi Gazdar and Neal Rosen and Solit, {David B.}",
year = "2008",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-08-2223",
language = "English (US)",
volume = "68",
pages = "9375--9383",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Genetic predictors of MEK dependence in non-small cell lung cancer

AU - Pratilas, Christine A.

AU - Hanrahan, Aphrothiti J.

AU - Halilovic, Ensar

AU - Persaud, Yogindra

AU - Soh, Junichi

AU - Chitale, Dhananjay

AU - Shigematsu, Hisayuki

AU - Yamamoto, Hiromasa

AU - Sawai, Ayana

AU - Janakiraman, Manickam

AU - Taylor, Barry S.

AU - Pao, William

AU - Toyooka, Shinichi

AU - Ladanyi, Marc

AU - Gazdar, Adi

AU - Rosen, Neal

AU - Solit, David B.

PY - 2008/11/15

Y1 - 2008/11/15

N2 - Hyperactivated extracellular signal-regulated kinase (ERK) signaling is common in human cancer and is often the result of activating mutations in BRAF,RAS,and upstream receptor tyrosine kinases. To characterize the mitogen-activated protein kinase/ERK kinase (MEK)/ERK dependence of lung cancers harboring BRAF kinase domain mutations,we screened a large panel of human lung cancer cell lines (n = 87) and tumors (n = 916) for BRAF mutations. We found that non-small cell lung cancers (NSCLC) cells with both V600E and non-V600E BRAF mutations were selectively sensitive to MEK inhibition compared with those harboring mutations in epidermal growth factor receptor (EGFR), KRAS, or ALK and ROS kinase fusions. Supporting its classification as a "driver" mutation in the cells in which it is expressed,MEK inhibition in V600EBRAF NSCLC cells led to substantial induction of apoptosis,comparab le with that seen with EGFR kinase inhibition in EGFR mutant NSCLC models. Despite high basal ERK phosphorylation, EGFR mutant cells were uniformly resistant to MEK inhibition. Conversely, BRAF mutant cell lines were resistant to EGFR inhibition. These data,together with the nonoverlapping pattern of EGFR and BRAF mutations in human lung cancer,suggest that these lesions define distinct clinical entities whose treatment should be guided by prospective real-time genotyping. To facilitate such an effort, we developed a mass spectrometry-based genotyping method for the detection of hotspot mutations in BRAF, KRAS,and EGFR. Using this assay,we confirmed that BRAF mutations can be identified in a minority of NSCLC tumors and that patients whose tumors harbor BRAF mutations have a distinct clinical profile compared with those whose tumors harbor kinase domain mutations in EGFR.

AB - Hyperactivated extracellular signal-regulated kinase (ERK) signaling is common in human cancer and is often the result of activating mutations in BRAF,RAS,and upstream receptor tyrosine kinases. To characterize the mitogen-activated protein kinase/ERK kinase (MEK)/ERK dependence of lung cancers harboring BRAF kinase domain mutations,we screened a large panel of human lung cancer cell lines (n = 87) and tumors (n = 916) for BRAF mutations. We found that non-small cell lung cancers (NSCLC) cells with both V600E and non-V600E BRAF mutations were selectively sensitive to MEK inhibition compared with those harboring mutations in epidermal growth factor receptor (EGFR), KRAS, or ALK and ROS kinase fusions. Supporting its classification as a "driver" mutation in the cells in which it is expressed,MEK inhibition in V600EBRAF NSCLC cells led to substantial induction of apoptosis,comparab le with that seen with EGFR kinase inhibition in EGFR mutant NSCLC models. Despite high basal ERK phosphorylation, EGFR mutant cells were uniformly resistant to MEK inhibition. Conversely, BRAF mutant cell lines were resistant to EGFR inhibition. These data,together with the nonoverlapping pattern of EGFR and BRAF mutations in human lung cancer,suggest that these lesions define distinct clinical entities whose treatment should be guided by prospective real-time genotyping. To facilitate such an effort, we developed a mass spectrometry-based genotyping method for the detection of hotspot mutations in BRAF, KRAS,and EGFR. Using this assay,we confirmed that BRAF mutations can be identified in a minority of NSCLC tumors and that patients whose tumors harbor BRAF mutations have a distinct clinical profile compared with those whose tumors harbor kinase domain mutations in EGFR.

UR - http://www.scopus.com/inward/record.url?scp=55949097252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949097252&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-2223

DO - 10.1158/0008-5472.CAN-08-2223

M3 - Article

C2 - 19010912

AN - SCOPUS:55949097252

VL - 68

SP - 9375

EP - 9383

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -